Table 2.
Demographics and Outcomes of Intensive Care Unit Patients Receiving Empirical or Preemptive Therapy of CAS, VOR or the Combination for Invasive Fungal Infectionsa
| Demographics and Outcomes | CAS (n = 30) | VOR (n = 27) | CAS+VOR (n = 34) | P-value |
|---|---|---|---|---|
| Sex (male/female) | 21/9 | 12/15 | 23/11 | 0.092 |
| Median age (range) (years) | 58.5 (28–97) | 60 (38–95) | 53 (19–85) | 0.061 |
| Median hospitalization days (range) | 19.5 (8–71) | 19 (8–41) | 18 (7–77) | 0.591 |
| Median duration of antifungal agents therapy (range) | 11 (7–32) | 11 (7–19) | 8.5 (7–27) | 0.087 |
| Hypoproteinemia (%) | 25 (83.3) | 19 (70.4) | 28 (82.4) | 0.445 |
| Continuous renal replacement therapy (%) | 6 (20.0) | 8 (29.6) | 6 (17.6) | 0.506 |
| Liver function (Child-Pugh A/B/C) | 14/14/2 | 15/10/2 | 12/21/1 | > 0.05 |
| Median creatinine clearance rate (range) (mL/min) | 81.0 (11.5–592.0) | 104.4 (26.6–556.4) | 84.9 (10.0–400.1) | 0.231 |
| Median APACHE II score (range) | 23 (7–39) | 18 (6–25) | 21 (7–25) | 0.232 |
| Median SOFA score (range) | 10 (2–16) | 7 (1–15) | 10 (5–12) | 0.503 |
| Increase in neutrophils (On admission/ infection occurs/at the end of treatment) | 20/24/18 | 21/24/23 | 20/23/23 | > 0.05 |
| Steroid use before or during therapy (%) | 20 (66.7) | 20 (74.1) | 32 (94.1) | 0.014 |
| Mechanical ventilation during therapy (%) | 15 (50.0) | 24 (88.9) | 25 (73.5) | 0.005 |
| Prophylactic antifungal treatment prior to infection (%) | 6 (20.0) | 5 (18.5) | 15 (44.1) | 0.052 |
| Breakthrough infection (%) | 0 (0) | 0 (0) | 0 (0) | — |
| Response to therapy (%) | 24 (80.0) | 16 (59.3) | 16 (47.1) | 0.025 |
| IFI-associated death within 90 days (%) | 0 (0) | 1 (3.7) | 0 (0) | 0.297 |
| All deaths within 90 days (%) | 8 (26.7) | 7 (25.9) | 16 (47.1) | 0.130 |
| All adverse events (%) | 6 (20.0) | 17 (63.0) | 11 (32.4) | 0.003 |
| Liver (%) | 2 (6.7) | 8 (29.6) | 4 (11.8) | 0.058 |
| Renal (%) | 2 (6.7) | 7 (25.9) | 4 (11.8) | 0.115 |
Note: aThe total number of intensive care unit patients receiving empirical or preemptive therapy of CAS, VOR or the combination was 91.